$ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Healthcare
Sector
Biotechnology
Industry
Vishwas Seshadri
CEO
136
Employees
$4.45
Current Price
$277.46M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $3,736.60 | 785 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $3,736.60 | 785 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $3,736.60 | 785 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 9 | 10 | $977,169.98 | 186,704 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 9 | 12 | $1,180,483.93 | 225,204 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 16, 2026 | Vazzano Joseph Walter Chief Financial Officer | Sale | 785 | $4.76 | $3,736.60 | View Details |
| Feb 2, 2026 | Silverstein Christine Berni Director | Sale | 20,070 | $5.09 | $102,168.34 | View Details |
| Feb 2, 2026 | Wuchterl Donald A. Director | Sale | 14,814 | $5.09 | $75,412.15 | View Details |
| Feb 2, 2026 | Crombez Eric Director | Sale | 16,284 | $5.09 | $82,895.33 | View Details |
| Feb 2, 2026 | Alland Leila Director | Sale | 18,065 | $5.09 | $91,961.69 | View Details |
| Feb 2, 2026 | Alvino Mark Director | Sale | 2,000 | $5.09 | $10,181.20 | View Details |
| Jan 22, 2026 | Vasanthavada Madhav Chief Commercial Officer | Sale | 12,610 | $5.29 | $66,657.72 | View Details |
| Jan 22, 2026 | Vazzano Joseph Walter Chief Financial Officer | Sale | 18,666 | $5.33 | $99,506.58 | View Details |
| Jan 22, 2026 | Seshadri Vishwas Director | Sale | 69,832 | $5.33 | $372,267.41 | View Details |
| Jan 22, 2026 | O'Malley Brendan M. SVP, Chief Legal Officer | Sale | 13,578 | $5.33 | $72,382.96 | View Details |
| Jan 21, 2026 | Alvino Mark Director | Sale | 13,500 | $5.23 | $70,573.95 | View Details |
| Dec 29, 2025 | Seshadri Vishwas Director | Sale | 25,000 | $5.31 | $132,740.00 | View Details |
23 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.33
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.35
Actual-$0.34
Beat
Revenue
Estimated$8.20M
Actual$5.42M
Miss
3 more earnings records available โ create a free account to see 12 months of history